International Genomics Consortium v. United States

104 Fed. Cl. 669, 2012 U.S. Claims LEXIS 583, 2012 WL 1925557
CourtUnited States Court of Federal Claims
DecidedMay 11, 2012
DocketNo. 12-047C
StatusPublished
Cited by10 cases

This text of 104 Fed. Cl. 669 (International Genomics Consortium v. United States) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
International Genomics Consortium v. United States, 104 Fed. Cl. 669, 2012 U.S. Claims LEXIS 583, 2012 WL 1925557 (uscfc 2012).

Opinion

OPINION

ALLEGRA, Judge:

In this preaward bid protest case, International Genomics Consortium (IGC or plaintiff), challenges a decision by the National Cancer Institute (NCI) to assign Science Applications International Corporation-Frederick (SAIC-F) the responsibility for procuring certain services needed to run a NCI project. The parties have filed cross-motions for judgment on the administrative record. In support of its motion, the United States argues that this court lacks jurisdiction to consider IGC’s challenges to NCI’s delegation of services to SAIC-F and to SAIC-F’s procurement of what are, in effect, subcontracted services. For the reasons that follow, the court GRANTS defendant’s cross-motion for judgment on the administrative record.2

I. BACKGROUND

The administrative record in this case reveals the following:

Plaintiff is a non-profit medical research organization that currently is one of a half a dozen or more contractors performing services for NCI as part of The Cancer Genome Atlas project (Atlas). Atlas is a large-scale collaborative effort by NCI and the National Institutes of Health to create a comprehensive collection of maps that chart the genomic changes that occur in various types of cancer. As part of this effort, plaintiff supplies various services as a Biospecimen Core Resource (BCR).

BCRs serve as the central coordinating hubs for Atlas. Under Atlas, so-called Tissue Source Sites obtain samples and conduct the preliminary pathology review. Those sites deliver the tissue samples to the BCRs, which refine them into high-[671]*671quality nucleic acids, and distribute these products downstream to Genome Sequencing Centers and Genome Characterization Centers. Prior to accepting samples, the BCRs train the Tissue Source Sites on how to obtain high-quality samples and the proper procedures for handling and shipping these samples. The BCRs also play a key role in helping to design and effectuate solutions for the capture of complete bios-pecimens and clinical data sets for these samples. Finally, the BCRs are responsible for transmitting all these data sets to the Atlas Data Coordinating Center and Sequence Data Archives, which eventually make the data available to investigators. The BCR function is not the only part of this process that NCI has contracted out. For example, the Data Coordinating Center is managed by another contractor, SRA International, while the Sequence Data Archives are run by the University of California at Santa Cruz. Still other contractors run other critical parts of the program and hundreds of private institutions act as Tissue Source Sites.

The Frederick National Lab of the National Cancer Institute (NCI-Frederick) is a government-owned, Federally-funded research and development center. Such centers are privately-run facilities used to meet long-term governmental research or development needs. See 48 C.F.R. § 35.017(a). NCI-Frederick provides a unique national resource for the development of new technologies and the translation of scientific discoveries into novel agents for the prevention, diagnosis, and treatment of cancer and acquired immune deficiency syndrome (AIDS). Since 2001, SAIC-F has operated NCI-Frederick under a contract with NCI.

Atlas began in 2006, as a pilot program run by SAIC-F. In August 2006, following a competitive procurement, SAIC-F awarded the BCR contract for this pilot program to plaintiff. Subsequently, in December 2009, SAIC-F awarded Nationwide Children’s Hospital (Nationwide) a contract to serve as a second BCR facility for the pilot program. Plaintiff and Nationwide were each funded to handle five hundred cases per month.

NCI’s most recent contract with SAIC-F, effective September 26, 2008, calls for it to provide scientific and business leadership, shared research support services, program-dedicated research, and business execution and operational support activities. The contract is designed to be flexible enough to permit SAIC-F to manage a wide range of new projects for NCI. By way of illustration, the statement of work in this contract specifies that SAIC-F is to “be responsible for the management and conduct of a broad range of research, research support, and administrative support services in response to the requirements of NCI/NIH scientific directions and priorities.” It further requires that the “Contractor maintain!] flexibility and [be] rapidly responsive in supporting the evolving on-going research, emerging technologies, and new research initiatives of the Government.” SAIC-F is also to support research “encompassing] a wide range of scientific disciplines” and “be responsible for the comprehensive operation of the NCI-Frederick and other NCI/NIH facilities or programs.” The statement of work lastly provides that “[a]ll ... contract requirements are defined by the Government,” adding that SAIC-F “shall be responsible for the establishment and management of new Government efforts requested by the [Government].”

One of the projects specifically mentioned in the statement of work is Atlas. Thus, NCI’s 2009 contract with SAIC-F provides:

The Contractor shall provide support to the Cancer Genome Anatomy Project (CGAP) and other efforts including The Cancer Genome Atlas (TCGA) and Cancer Genetic Markers of Susceptibility (cGEMs) directed toward elucidating the molecular events in normal, pre-cancer and cancer cells. The Contractor will assist in the identification of institutions having unique capabilities to conduct the analysis of the cellular genes and gene products, including DNA sequencing and the construction of expression libraries, and will access such institutions through its subcontracting program. The Contractor shall also provide research support to these efforts through its Advanced Technology Program.

[672]*672The contract contains a detailed subcontracting plan, as well as several other references to SAIC-F’s ability to subcontract certain services.

In November 2009, with the pilot phase of Atlas set to conclude, defendant modified SAIC-F’s contract to deobligate some funding for Atlas. In 2010, defendant announced that the Atlas project would exit the pilot phase and become fully operational. Rather than delegating that program back to SAIC-F, NCI initially chose to run Atlas itself. In September 2010, defendant conducted a procurement for BCR services for the project. Following a competition, defendant awarded contracts to plaintiff and to Nationwide, effective September 24, 2010, to continue performing BCR services for Atlas. These contracts were managed directly by NCI. Plaintiffs contract was originally set to expire in March 2012, with a series of options that could stretch the period of performance through 2016.

In March 2011, Dr. Kenna Shaw, a NCI employee, notified her supervisors that the BCR facilities were not being used to capacity, and recommended awarding the function to a single BCR facility. She opined that Nationwide was outperforming plaintiff and that, in the event of a consolidation, Nationwide should be the sole BCR facility. NCI officials discussed this idea, but came to no conclusion. In April of 2011, Dr. Shaw became Atlas’ Deputy Director and the contracting officer’s technical representative (COTR) on the BCR contracts.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Validata Chemical Services v. United States Department of Energy
169 F. Supp. 3d 69 (District of Columbia, 2016)
Tenica & Associates, Inc v. United States
123 Fed. Cl. 166 (Federal Claims, 2015)
Coast Professional, Inc. v. United States
120 Fed. Cl. 727 (Federal Claims, 2015)
Vfa, Inc. v. United States
118 Fed. Cl. 735 (Federal Claims, 2014)
American Apparel, Inc. v. United States
108 Fed. Cl. 11 (Federal Claims, 2012)
Reema Consulting Services, Inc. v. United States
107 Fed. Cl. 519 (Federal Claims, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
104 Fed. Cl. 669, 2012 U.S. Claims LEXIS 583, 2012 WL 1925557, Counsel Stack Legal Research, https://law.counselstack.com/opinion/international-genomics-consortium-v-united-states-uscfc-2012.